Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 15/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SLC26A6 | Q9BXS9 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29897192 | 1.00 | RET (0.50) | RETMAPTCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL29897213 | 0.92 | RET (0.53) | RETCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL21179024 | 0.92 | RET (0.53) | RETCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL21179162 | 0.90 | RET (0.62) | RETCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL29897230 | 0.90 | RET (0.62) | RETCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL21178980 | 0.86 | RET (0.60) | RETCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL29897216 | 0.86 | RET (0.60) | RETCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL21179165 | 0.86 | RET (0.58) | RETCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL21178913 | 0.86 | RET (0.58) | RETCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL29897201 | 0.86 | RET (0.58) | RETCYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472802-B2 | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-11472802-B2 | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2022-10-18 | — | — | US | disclosed |
| CN-111615514-B | Substituted pyrazolo [4,3-C ] pyridine compounds as RET kinase inhibitors | 奥瑞生物药品公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-3740486-A1 | SUBSTITUTED PYRAZOLYL[4,3-C]PYRIDINECOMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20200339579-A1 | SUBSTITUTED PYRAZOLYL[4,3-C]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2020-10-29 | — | — | US | disclosed |
| US-20200339579-A1 | SUBSTITUTED PYRAZOLYL[4,3-C]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2020-10-29 | — | — | US | disclosed |
| CN-111615514-A | Substituted pyrazolo [4,3-C ] pyridine compounds as RET kinase inhibitors | 奥瑞生物药品公司 | 2020-09-01 | — | — | CN | disclosed |
| WO-2019143994-A1 | SUBSTITUTED PYRAZOLYL[4,3-C]PYRIDINECOMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019143994-A1 | SUBSTITUTED PYRAZOLYL[4,3-C]PYRIDINECOMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339579-A1 | SUBSTITUTED PYRAZOLYL[4,3-C]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | RET 1/4885MAPT 128/4885CYP1A2 3855/4885 |
| US-11472802-B2 | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | RET 1/4885MAPT 128/4885CYP1A2 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.